Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial
Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial
复制标题
DOI：
10.1016/j.rmed.2007.12.019
复制
发表时间：
2008-04-01
影响因子：
4.3
通讯作者：
Denis-Mize, Kimberly
中科院分区：
文献类型：
--
作者：
Tashkin, Donald P.;Littner, Michael;Denis-Mize, Kimberly
通过干粉吸入器（DPI）向噻托溴铵中添加长效β(2)激动剂（LABA），与单独使用任何一种产品相比，可显著增加和持续慢性阻塞性肺疾病（COPD）患者的支气管扩张。为了证明雾化LABA的类似益处，进行了一项安慰剂对照试验，以评估富马酸福莫特罗吸入溶液在接受噻托溴铵作为COPD维持治疗的受试者中的疗效和安全性。经过7-14天的筛查期，每天一次使用噻托溴胺18 μ g，诊断为慢性阻塞性肺病的受试者(>= 25%至
Adding a long-acting beta(2)-agonist (LABA) by dry powder inhaler (DPI) to tiotropium provides significantly increased and sustained bronchodilation in chronic obstructive pulmonary disease (COPD) patients over either product alone. To demonstrate similar benefits with a nebulized LABA, a placebo-controlled trial was conducted to evaluate the efficacy and safety of formoterol fumarate inhalation solution in subjects receiving tiotropium as a maintenance treatment for COPD.After a 7-14-day screening period using tiotropium 18 mu g once daily, subjects with diagnosed COPD (>= 25% to